Inovio Pharma

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Relative Strength Index

Score

-0.65

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 12 36.1 0.25% 0.33% 20.3% -10.5% -33.6%
SHORT 12 26.9 0.25% 0.33% 21.3% -13.4% -56.9%

Summary

Technical Analysis


The relative strength index (RSI) is a momentum indicator developed by noted technical analyst Welles Wilder which compares the magnitude of recent gains and losses over a specified time period to measure speed and change of price movements of a security. It is primarily used to attempt to identify overbought or oversold conditions in the trading of an asset.

Calculation: Relative Strength Index (RSI):
1) RSI = 100 - 100 / (1 + RS);
2) RS = Average Gain / Average Loss;


PROFILE: Inovio Pharma (INO)


Stock Exchange: NASDAQ
Company: Inovio Pharma
Ticker Codes: | INO | NASDAQ:INO |

About Inovio Pharma (NASDAQ:INO):

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Top 10:

Relative Strength Index

Download
Company Close Change(%) Volume Value Signal
NH Nanthealth 1.69 9.7 129,884 52.98 NEUTRAL
QDEL Quidel 95.33 8.7 895,602 61.81 NEUTRAL
RVNC Revance Therapeutics 16.48 8.2 717,681 44.62 NEUTRAL
ANGI Angie'S List Inc 5.34 7.7 1,758,757 42.22 NEUTRAL
PRTK Paratek Pharma 3.42 7.2 427,643 48.56 NEUTRAL
MCRB Seres Theraptc 3.74 6.9 75,031 57.87 NEUTRAL
DXCM Dexcom 265.26 6 658,391 57.72 NEUTRAL
EZPW Ezcorp Inc 4.02 5.8 583,071 45.11 NEUTRAL
TLGT Teligent 0.29 5.7 67,532 40.76 NEUTRAL
ITCI Intra-Cellular 16.36 5.3 405,147 44.42 NEUTRAL